The Biostatistics Core provides a broad array of statistical services in support of the three Projects and other three Cores. The Core will provide regular advice on Experimental design, such as selection of end points, sample size and power, and optimal use of animals. The Core is responsible for all clinical data management as it relates to the Blood and Marrow Transplant Program in a secure central location. The Core will perform expert statistical analyses in a format consistent between Projects using techniques that are state of the art in practice. The Core will also facilitate data sharing with the Program as well as the general scientific community. The Core is staffed by experienced biostatisticians who have daily working relationships with the Project investigators. The Core biostatisticians have been an integral part in the development of the Program and have participated in this PPG for most of its history. The Core has access to all needed software. This dedicated Biostatistics Core provides easy access to Program investigators and has allowed biostatisticians to specialize in the specific Project areas, gaining working knowledge in the field helping provide the tailored biostatistical support.

Public Health Relevance

The primary objective of the Biostatistics Core is to contribute to the science and operation of the program project by participating fully in its activities. Core Statisticians have broad long-standing expertise in Experimental design, data collection, data storage, data analysis, and interpretation of results incorporating novel and complex statistical procedures as needed. By providing expertise research methodology and logistical support to data analytic activities with each Project, this Core will enhance data interpretation and scientific productivity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-22
Application #
9158125
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
22
Fiscal Year
2016
Total Cost
$139,441
Indirect Cost
$47,689
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Osborn, Mark J; Lees, Christopher J; McElroy, Amber N et al. (2018) CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. Int J Mol Sci 19:
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 395 publications